ArticleScientific reports2012
Next-generation sequencing coupled with a cell-free display technology for high-throughput production of reliable interactome data.
Article in Scientific reports, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- Article
- More than one way to bind to cholesterol: atypical variants of membrane-binding domain of perfringolysin O selected by ribosome display.RSC advances · 2020Article
- High throughput sequencing of in vitro selections of mRNA-displayed peptides: data analysis and applications.Physical chemistry chemical physics : PCCP · 2020Review
- Next-generation technologies for multiomics approaches including interactome sequencing.BioMed research international · 2015Review
- Liposome display for in vitro selection and evolution of membrane proteins.Nature protocols · 2014Article
- Molecular network analysis enhances understanding of the biology of mental disorders.BioEssays : news and reviews in molecular, cellular and developmental biology · 2014Review
- Towards personalized medicine mediated by in vitro virus-based interactome approaches.International journal of molecular sciences · 2014Review
- Beyond GWAS in COPD: probing the landscape between gene-set associations, genome-wide associations and protein-protein interaction networks.Human heredity · 2014Article
- DNA sequencing methods in human genetics and disease research.F1000prime reports · 2013Review
- Efficiency of puromycin-based technologies mediated by release factors and a ribosome recycling factor.Protein engineering, design & selection : PEDS · 2013Article
- Development of Next-Generation Peptide Binders Using In vitro Display Technologies and Their Potential Applications.Frontiers in immunology · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Next-generation sequencing (NGS) has been applied to various kinds of omics studies, resulting in many biological and medical discoveries. However, high-throughput protein-protein interactome datasets derived from detection by sequencing are scarce, because protein-protein interaction analysis requires many cell manipulations to examine the interactions. The low reliability of the high-throughput data is also a problem. Here, we describe a cell-free display technology combined with NGS that can improve both the coverage and reliability of interactome datasets. The completely cell-free method gives a high-throughput and a large detection space, testing the interactions without using clones. The quantitative information provided by NGS reduces the number of false positives. The method is suitable for the in vitro detection of proteins that interact not only with the bait protein, but also with DNA, RNA and chemical compounds. Thus, it could become a universal approach for exploring the large space of protein sequences and interactome networks.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.